Athira Pharma Toekomstige groei
Future criteriumcontroles 0/6
Athira Pharma zal naar verwachting dalen met 25.3% per jaar. De winst per aandeel zal naar verwachting groeien met 32% per jaar.
Belangrijke informatie
25.3%
Groei van de winst
32.0%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 23.7% |
Inkomstengroei | n/a |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 13 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?
Feb 16Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
Nov 02Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
May 29Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
Jan 04Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis
Oct 17Athira Pharma GAAP EPS of -$0.65
Aug 15We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Aug 09Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug
Jun 22Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth
May 08We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
Jan 11Athira Pharma: What, Exactly, Did The CEO Do?
Jun 29Athira Pharma falls after the decision to place CEO on temporary leave
Jun 17Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy
Jun 07We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth
May 24We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Feb 08Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach
Jan 11Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like
Dec 18Athira Pharma nabs research grant of $15M from NIH
Dec 08Athira Pharma reports Q3 results
Nov 12Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | N/A | -47 | -149 | N/A | 2 |
12/31/2025 | N/A | -61 | -132 | N/A | 3 |
12/31/2024 | N/A | -98 | -96 | N/A | 4 |
9/30/2024 | N/A | -109 | -97 | -97 | N/A |
6/30/2024 | N/A | -113 | -98 | -98 | N/A |
3/31/2024 | N/A | -116 | -100 | -100 | N/A |
12/31/2023 | N/A | -118 | -101 | -101 | N/A |
9/30/2023 | N/A | -121 | -90 | -90 | N/A |
6/30/2023 | N/A | -108 | -88 | -88 | N/A |
3/31/2023 | N/A | -102 | -83 | -82 | N/A |
12/31/2022 | N/A | -96 | -74 | -72 | N/A |
9/30/2022 | N/A | -82 | -77 | -75 | N/A |
6/30/2022 | N/A | -77 | -66 | -64 | N/A |
3/31/2022 | N/A | -67 | -54 | -52 | N/A |
12/31/2021 | N/A | -55 | -45 | -43 | N/A |
9/30/2021 | N/A | -46 | -38 | -36 | N/A |
6/30/2021 | N/A | -39 | -37 | -35 | N/A |
3/31/2021 | N/A | -27 | -33 | -30 | N/A |
12/31/2020 | N/A | -20 | -26 | -24 | N/A |
9/30/2020 | N/A | -13 | -15 | -14 | N/A |
6/30/2020 | N/A | -6 | -6 | -6 | N/A |
3/31/2020 | N/A | -6 | -4 | -4 | N/A |
12/31/2019 | N/A | -5 | -4 | -4 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat ATHA de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat ATHA de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat ATHA de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van ATHA naar verwachting sneller zal groeien dan de markt US.
Hoge groei-inkomsten: Er wordt verwacht dat ATHA volgend jaar geen omzet zal hebben.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ATHA naar verwachting over 3 jaar hoog zal zijn